Kuros Biosciences AG completes rights offering and share placement
Kuros Biosciences (SIX: KURN) completes a rights offering and share placement in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 each were offered at an offer price of CHF 2.50 per share. Total gross proceeds raised from the capital increase amount to CHF 16.1 million. With the gross proceeds raised in the capital increase, the commercialization of MagnetOs can be progressed as well as the phase 2 clinical study of the Company’s proprietary fibrin-PTH (KUR-113) product in spinal fusion can continue as planned.
VISCHER AG advised Kuros Biosciences with Matthias Staehelin (Partner, Corporate), Angelo Imperiale (Associate, Corporate) and Adrian Briner (Associate, Tax).